20000250-P

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:
C07D 405/06, 405/14, 409/14, 405/12, 417/06, 401/06, 491/04, 471/04, 493/10, A61K 31/44, 31/47 // (C07D 491/04, 317:00, 221:00) (C07D 471/04, 221:00)

A1

(11) International Publication Number: **WO 99/26943**

(43) International Publication Date: 3 June 1999 (03.06.99)

(21) International Application Number: PCT/US98/24523

(22) International Filing Date: 23 November 1998 (23.11.98)

(30) Priority Data:
08/977,979 25 November 1997 (25.11.97) US

(71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).


(72) Inventors: CHACKALAMANNIL, Samuel; 790 Stratford Road, East Brunswick, NJ 08816 (US). ASBEROM, Theodros; 17 Stone Drive, West Orange, NJ 07052 (US). XIA, Yan; 137 Christie Street, Edison, NJ 08820 (US). DOLLER, Dario; 186 Filly Drive, North Wales, PA 19454 (US). CLASBY, Martin, C.; 231 Spruce Mill Lane, Scotch Plains, NJ 07076 (US). CZARNIECKI, Michael, F.; 30 Gildersleeve Place, Watchung, NJ 07060 (US).

(74) Agents: MAGATTI, Anita, W. et al.; Schering-Plough Corporation, Patent Dept., K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).


(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.


(54) Title: THROMBIN RECEPTOR ANTAGONISTS



(I)



(A)



(B)

(57) Abstract

Heterocyclic-substituted tricyclics of formula (I) or a pharmaceutically acceptable salt thereof, wherein: the single dotted line represents an optional double bond; the double dotted line represents an optional single bond; n is 0-2; Q is optionally substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl; Het is an optionally substituted mono-, bi- or tricyclic heteroaromatic group; B is $-(CH_2)_{n3}-$, wherein n_3 is 0-5, $-CH_2-O-$, $-CH_2S-$, $-CH_2-NR^6-$, $-C(O)NR^6-$, $-NR^6C(O)-$, (a), optionally substituted alkenyl or optionally substituted alkynyl; X is -O- or $-NR^6-$ when the double dotted line represents a single bond, or X is -OH or $-NHR^{20}$ when the bond is absent; Y is =O, =S, (H, H), (H, OH) or (H, C_1-C_6 alkoxy) when the double dotted line represents a single bond, or when the bond is absent, Y is =O, (H, H), (H, OH), (H, SH) or (H, C_1-C_6 alkoxy); R^{15} is absent when the double dotted line represents a single bond and is H, $-NR^{18}R^{19}$, or $-OR^{17}$ when the bond is absent; or Y is (A) or (B) and R^{15} is H or C_1-C_6 alkyl; are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds.